ARS-2, Low-Dose Intranasal Epinephrine, Improves Urticaria Scores in Patients with Frequent Urticaria Flares: Phase 2 Study Results

While symptoms of chronic spontaneous urticaria are typically controlled with antihistamines or anti-IgE antibodies, many patients still experience periodic acute exacerbations. A low-dose intranasal epinephrine spray (ARS-2) is being developed as a needle-free option for the treatment of severe allergic reactions and is expected to be a highly effective, safe, and easy-to-use option for the rapid treatment of urticaria exacerbations.